Home Multimedia Podcasts Subvisible Particles in Biotech Drugs Subvisible Particles in Biotech Drugs August 23, 2011 E. Morrey Atkinson, Ph.D., CSO, VP of R&D, Cook Pharmica /wp-content/uploads/2018/09/gencast_082211.mp3 Drug research and developmentPharmacology Also of Interest StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Alexandria Founder Talks Takeda, Massachusetts, NYC, and 30th Anniversary Lab Space Giant Alexandria Real Estate Navigates AI’s Impact on Biopharma Digital Twin Approach Triples Productivity for Lyophilization 89bio’s MASH Drug Begins Phase III, Aiming to Stand Out in Growing Field With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate Related Media Emerging Markets Collaborate to Succeed in Post-Pandemic World Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development Moving the Drug Pipeline Forward with Mechanistic Modeling Related Content StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Alexandria Founder Talks Takeda, Massachusetts, NYC, and 30th Anniversary Lab Space Giant Alexandria Real Estate Navigates AI’s Impact on Biopharma Digital Twin Approach Triples Productivity for Lyophilization